• Anixa Biosciences won a South Korean composition-of-matter patent covering its breast cancer vaccine technology, extending protection through 2040.
• The patent, exclusively licensed from Cleveland Clinic, strengthens the company’s international intellectual property position for the program.
• Anixa cited Phase 1 results showing the vaccine was safe and well tolerated, generating immune responses in 74% of participants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93670) on June 29, 2026, and is solely responsible for the information contained therein.